Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal centre and posts germinal centre B-cells.
Diffuse Large B-Cell Lymphoma Epidemiological Segmentation
The Epidemiological Segmentation of Diffuse Large B-Cell Lymphoma in 7MM from 2017 to 2030 is segmented as:-
- Total Incident Cases Of Diffuse Large B-Cell Lymphoma
- Gender-Specific Cases Of Diffuse Large B-Cell Lymphoma
- Age-Specific Cases Of Diffuse Large B-Cell Lymphoma
- Type-Specific Cases Of Diffuse Large B-Cell Lymphoma
- Stage-Specific Cases Of Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma Epidemiology
- The total incident cases of DLBCL in 7MM in 2017 were 67,743
- The incident population of DLBCL in the United States were 28,659 in 2017
- The age-group with the highest incidence of DLBCL among 7MM in 2017 was observed in the 65–74 years
- Males have higher incident cases of DLBCL as compared to females
Diffuse Large B-Cell Lymphoma Market
The market Size of DLBCL in 7MM in 2017 was USD 2,655 million
Diffuse Large B-Cell Lymphoma Market Drivers
- Rising Incidence among Aging population
- Increase in R&D
- CAR-T therapies approvals
Diffuse Large B-Cell Lymphoma Market Barriers
- Availability of defined diagnostic tools
- Delay in Diagnosis
- The high cost of treatment
Diffuse Large B-Cell Lymphoma Emerging Drugs
The emerging drugs of the Diffuse Large B-Cell Lymphoma market are
- Lisocabtagene maraleucel
- Brentuximab Vedotin
- Loncastuximab Tesirine
- Tafasitamab
- Treakisym
- Enzastaurin (DB102)
- Ublituximab + Umbralisib
- Blinatumomab
- Aliqopa (Copanlisib/BAY 80-6946)
- Imbruvica (Ibrutinib)
- Odronextamab (REGN1979)
- Imfinzi (durvalumab): Parsaclisib (INCB050465)
- TC 110
- DPX-Survivac
- Acalabrutinib
- AUTO3
- Obinutuzumab
- CLR 131
- Debio1562
And many others.
Diffuse Large B-Cell Lymphoma Key Players
The key players in the Diffuse Large B-Cell Lymphoma market are
- Bristol-Myers Squibb
- Seattle Genetics
- Takeda
- ADC Therapeutics
- Morphosys
- Incyte
- SymBio Pharmaceuticals
- Denovo Biopharma
- TG Therapeutics
- Amgen
- Bayer
- Janssen/Pharmacyclics (AbbVie Company)
- Regeneron Pharmaceuticals
- Celgene/Bristol Myers Squibb
- Incyte Corporation
- TCR2 Therapeutics
- IMV, inc. & Merck
- AstraZeneca
- Autolus Therapeutics
- Hoffmann-La Roche
- Cellectar Bioscience
- Debiopharm International
And many others.